Related Experiment Video
Updated: Jan 14, 2026
Acupoint Application as a Traditional Chinese Medicine Treatment for Fatigue Associated with Chronic Obstructive Pulmonary Disease
Published on: September 5, 2025
Evaluating the Effectiveness of Triple Therapy in Chronic Obstructive Pulmonary Disease Patients: An Asian
Chih-Yuan Sung1, Chuan-Wei Shen1, Ye Gu1
1School of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan, Republic of China.
Background:
The optimal treatment strategy for chronic obstructive pulmonary disease (COPD) remains debated, especially when choosing between triple therapy and long-acting beta agonist (LABA) + long-acting muscarinic antagonist (LAMA). This study aimed to develop a model that simulates real-world prescription patterns and compares the effectiveness of these two treatment options.
Methods:
This population-based cohort study used Taiwan's National Health Insurance Research Database to follow COPD patients who had been on LABA plus inhaled corticosteroids (ICSs) for more than 28 days. These patients were followed until they either upgraded to triple therapy or switched to LABA plus LAMA. The study enrolled patients from 2013 to 2021. Cox proportional hazard models were used to evaluate the risk of seven individual outcomes, including mortality, COPD exacerbations, acute respiratory failure, pneumonia, and respiratory-related admissions, adjusting for fixed and time-dependent variables.
Results:
Among the 20,997 included patients (mean (standard deviation (SD)) age: 66.06 (11.54) years; 12,977 males (61.80%)), 16,792 (79.97%) were in the triple therapy group, and 4,205 (20.03%) were in LABA plus LAMA group. The triple therapy group showed significantly higher relative risks in several outcomes: composite outcome (adjusted hazard ratio (aHR): 1.162; 95% confidence interval (CI): 1.098 - 1.230; P < 0.0001), acute respiratory failure (aHR: 1.315; 95% CI: 1.047 - 1.653; P = 0.0186), severe acute exacerbation (aHR: 1.346; 95% CI: 1.078 - 1.682; P = 0.0088), pneumonia (aHR: 1.221; 95% CI: 1.109 - 1.344; P < 0.0001) and respiratory-related admission (aHR: 1.264; 95% CI: 1.157 - 1.382; P < 0.0001), indicating superior effectiveness of LABA plus LAMA in these indicators.
Conclusions:
In conclusion, in COPD patients, the combination of LABA plus LAMA can significantly improve many major symptoms and reduce the frequency of exacerbations.
More Related Videos
07:10Home-Based Prescribed Pulmonary Exercise in Patients with Stable Chronic Obstructive Pulmonary Disease
Published on: August 24, 2019
04:03Author Spotlight: Evaluating the Therapeutic Efficacy of Moving Cupping Along Meridians for Acute Exacerbation of COPD
Published on: September 27, 2024
Related Concept Videos
01:29Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:27Chronic Obstructive Pulmonary Disease-IV: Assessement and Diagnostic Studies
Medical History
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:25Chronic Obstructive Pulmonary Disease-III: Symptoms and Complications.
Symptoms of COPD can be classified as primary or systemic. Primary symptoms relate to reduced airflow, while systemic or extrapulmonary symptoms relate to COPD's broader impact on the body.
Primary Symptoms of COPD:
01:22Chronic Obstructive Pulmonary Disease
Smoking is a primary risk factor for COPD, with over 80% of patients having a history of it. Patients typically experience progressive dyspnea or labored breathing, frequent coughing, and recurrent pulmonary infections. Many eventually succumb to respiratory failure, characterized by...